🍽️ formestane,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Aromatase Inhibition: Formestane works by inhibiting the enzyme aromatase, which is responsible for the conversion of androgens (such as testosterone) into estrogens (such as estradiol). By inhibiting aromatase, formestane reduces the production of estrogen in the body.

  2. Breast Cancer Treatment: Formestane is used as adjuvant therapy (therapy given after primary treatment to reduce the risk of cancer recurrence) in postmenopausal women with hormone receptor-positive breast cancer. It may also be used in the treatment of advanced or metastatic breast cancer that has not responded to other treatments.

  3. Hormone Therapy: Formestane is often used in combination with other hormonal therapies, such as selective estrogen receptor modulators (SERMs) or aromatase inhibitors, to further suppress estrogen production or block estrogen receptors in breast cancer cells.

  4. Estrogen Suppression: By reducing estrogen levels in the body, formestane helps to slow down or stop the growth of estrogen-sensitive breast cancer cells. This can lead to tumor shrinkage and improved survival outcomes in breast cancer patients.

  5. Side Effects: Common side effects of formestane may include hot flashes, sweating, fatigue, nausea, vomiting, loss of appetite, joint pain, headache, dizziness, mood changes, and vaginal dryness. These side effects are usually temporary and may improve over time.

  6. Bone Health: Long-term use of aromatase inhibitors like formestane may increase the risk of osteoporosis and bone fractures due to reduced estrogen levels. Therefore, bone mineral density may need to be monitored regularly in patients receiving formestane therapy, and supplementation with calcium and vitamin D may be recommended.

  7. Cardiovascular Health: Estrogen has cardio-protective effects, and its suppression by formestane may increase the risk of cardiovascular events such as heart attack and stroke. Patients should be monitored for cardiovascular risk factors, and lifestyle modifications may be advised to reduce cardiovascular risk.

  8. Endocrine Effects: Formestane may affect the function of the hypothalamic-pituitary-adrenal (HPA) axis and other endocrine glands. Regular monitoring of hormone levels, including cortisol and thyroid hormones, may be necessary during formestane therapy.

  9. Interactions: Formestane may interact with other medications, including hormonal therapies, and supplements. Patients should inform their healthcare provider about all medications and supplements they are taking before starting formestane therapy.

  10. Pregnancy and Lactation: Formestane is contraindicated during pregnancy and lactation due to its potential to cause harm to the fetus or nursing infant. Women of childbearing age should use effective contraception during formestane therapy.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of formestane,(prescription) On Probiotics

Rank Probiotic Impact

Bacteria Impacted by formestane,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Ruminococcus genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Roseburia hominis species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of formestane,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 0.5 0.5
Age-Related Macular Degeneration and Glaucoma 0.1 0.3 -2
Allergic Rhinitis (Hay Fever) 0.3 0.3
Allergies 0.2 -0.2
Allergy to milk products 0.1 0.3 -2
Alopecia (Hair Loss) 0.6 0.6
Alzheimer's disease 0.4 0.4 0
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.1 -0.1
Ankylosing spondylitis 0.6 0.1 5
Anorexia Nervosa 0.3 0.2 0.5
Asthma 0.1 -0.1
Atherosclerosis 0.1 0.1 0
Atrial fibrillation 0.4 0.3 0.33
Autism 0.5 0.5 0
Bipolar Disorder 0.4 0.2 1
Brain Trauma 0.1 -0.1
Carcinoma 0.4 0.4 0
Celiac Disease 0.4 -0.4
Cerebral Palsy 0.2 -0.2
Chronic Fatigue Syndrome 0.4 0.6 -0.5
Chronic Kidney Disease 0.3 0.1 2
Chronic Lyme 0.1 -0.1
Chronic Obstructive Pulmonary Disease (COPD) 0.1 -0.1
Coagulation / Micro clot triggering bacteria 0.3 0.2 0.5
Colorectal Cancer 0.5 0.5
Constipation 0.1 -0.1
Coronary artery disease 0.1 0.1
COVID-19 0.4 0.4 0
Crohn's Disease 0.5 0.5 0
cystic fibrosis 0.1 -0.1
deep vein thrombosis 0.2 -0.2
Depression 1.4 0.5 1.8
Endometriosis 0.3 0.1 2
Epilepsy 0.3 -0.3
Fibromyalgia 0.4 0.4
Functional constipation / chronic idiopathic constipation 0.4 0.1 3
gallstone disease (gsd) 0.4 0.1 3
Graves' disease 0.3 0.1 2
Hashimoto's thyroiditis 0.1 0.1
Histamine Issues 0.1 0.1
hyperglycemia 0.3 -0.3
hypertension (High Blood Pressure 0.4 0.3 0.33
Hypoxia 0.3 0.3
Inflammatory Bowel Disease 1 -1
Insomnia 0.1 -0.1
Intracranial aneurysms 0.4 0.4
Irritable Bowel Syndrome 0.2 0.4 -1
Liver Cirrhosis 0.5 0.2 1.5
Long COVID 0.3 0.7 -1.33
Low bone mineral density 0.1 -0.1
Lung Cancer 0.1 -0.1
Mast Cell Issues / mastitis 0.1 -0.1
ME/CFS without IBS 0.1 0.6 -5
Metabolic Syndrome 0.5 0.7 -0.4
Mood Disorders 1.5 0.5 2
Multiple Sclerosis 0.4 1.2 -2
Multiple system atrophy (MSA) 0.2 0.1 1
neuropathic pain 0.2 -0.2
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.1 -0.1
Obesity 0.7 0.4 0.75
obsessive-compulsive disorder 0.5 0.5
Osteoarthritis 0.1 -0.1
Osteoporosis 0.1 0.1
Parkinson's Disease 0.3 0.2 0.5
Polycystic ovary syndrome 0.4 0.3 0.33
Premenstrual dysphoric disorder 0.3 -0.3
Psoriasis 0.1 1.1 -10
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.5 0.1 4
Rosacea 0.1 0.1 0
Schizophrenia 0.4 0.2 1
scoliosis 0.1 -0.1
Sjögren syndrome 0.3 0.3 0
Sleep Apnea 0.1 0.1 0
Stress / posttraumatic stress disorder 0.4 0.1 3
Systemic Lupus Erythematosus 0.3 0.2 0.5
Tic Disorder 0.1 0.1
Type 1 Diabetes 0.1 0.1 0
Type 2 Diabetes 0.5 0.5 0
Ulcerative colitis 0.4 -0.4
Unhealthy Ageing 0.1 -0.1

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.222.64 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.222.64 ]